ARNA - Arena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
64.66
-0.69 (-1.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close65.35
Open65.87
Bid62.15 x 800
Ask68.10 x 800
Day's Range63.83 - 67.54
52 Week Range32.95 - 69.75
Volume1,251,408
Avg. Volume813,426
Market Cap3.255B
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-6.47
Earnings DateAug 05, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
57% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Aren’t Done Buying Arena Pharmaceuticals, Inc. (ARNA)
    Insider Monkey

    Hedge Funds Aren’t Done Buying Arena Pharmaceuticals, Inc. (ARNA)

    In this article we will check out the progression of hedge fund sentiment towards Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

  • Why Bristol Myers' Success In Ulcerative Colitis Sent Arena Stock Flying
    Investor's Business Daily

    Why Bristol Myers' Success In Ulcerative Colitis Sent Arena Stock Flying

    Bristol Myers Squibb reported positive ulcerative colitis treatment data Tuesday helping shares of rival Arena Pharmaceuticals to pop. Arena is testing a similar drug called etrasimod.

  • Here's Why Arena Pharmaceuticals Jumped Higher Today
    Motley Fool

    Here's Why Arena Pharmaceuticals Jumped Higher Today

    Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are up 13% at 2:13 p.m. EDT because its rival, Bristol Myers Squibb (NYSE: BMY), reported positive data on Zeposia in patients with ulcerative colitis. Zeposia targets the sphingosine-1-phosphate (S1P) receptor, just like Arena's etrasimod. Typically, good data from a rival drugmaker would send shares down, not up, but ulcerative colitis is a common enough disease -- around a million Americans have it -- that there's enough room in the marketplace for more than one drug.

  • Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
    PR Newswire

    Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $50.00 per share, including 825,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Arena. Including the option exercise, the aggregate gross proceeds to Arena from the offering were approximately $316.3 million, before deducting the underwriting discounts and commissions and offering expenses.

  • Moving Average Crossover Alert: Arena Pharmaceuticals
    Zacks

    Moving Average Crossover Alert: Arena Pharmaceuticals

    Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

  • Thomson Reuters StreetEvents

    Edited Transcript of ARNA earnings conference call or presentation 7-May-20 8:30pm GMT

    Q1 2020 Arena Pharmaceuticals Inc Earnings Call

  • Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    PR Newswire

    Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena. The gross proceeds from the offering are expected to be $275.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on June 1, 2020, subject to customary closing conditions. In addition, Arena has granted the underwriters of the offering a 30-day option to purchase up to an additional 825,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

  • Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
    PR Newswire

    Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by Arena. In addition, Arena intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
    PR Newswire

    Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 2b ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe atopic dermatitis. The trial enrolled 140 patients at study sites across the United States, Canada and Australia, with a primary efficacy endpoint of percent change in Eczema Area and Severity Index (EASI) from baseline to week 12.

  • Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
    PR Newswire

    Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Arena is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.

  • Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    PR Newswire

    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 113,175 shares of its common stock to 13 new employees and 16,510 inducement restricted stock units ("RSUs") to ten new employees. The inducement stock options and RSUs have a grant date and vesting commencement date of May 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).

  • GlobeNewswire

    Galecto Appoints New Chair and Strengthens Board of Directors

    Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its Board of Directors has appointed Amit Munshi as its new Chairman. Galecto also announced the appointment of David Shapiro MD, the former Chief Medical Officer of Intercept Pharmaceuticals, to its Board of Directors.

  • Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
    PR Newswire

    Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences.

  • Is Arena (ARNA) Stock a Solid Choice Right Now?
    Zacks

    Is Arena (ARNA) Stock a Solid Choice Right Now?

    Arena (ARNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Earnings Update: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Just Reported And Analysts Are Trimming Their Forecasts
    Simply Wall St.

    Earnings Update: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Just Reported And Analysts Are Trimming Their Forecasts

    Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had a good week, as its shares rose 9.6% to close at US$52.10...

  • Arena Pharmaceuticals Inc (ARNA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Arena Pharmaceuticals Inc (ARNA) Q1 2020 Earnings Call Transcript

    Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA)Q1 2020 Earnings CallMay 7, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorSo good day, everyone, and welcome to Arena Pharmaceuticals Corporate Conference Call.

  • Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected
    Zacks

    Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected

    Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

  • Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results
    PR Newswire

    Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

  • Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13
    PR Newswire

    Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Preston Klassen, MD, MHS, the Company's Executive Vice President, Head of Research & Development, is scheduled to participate in a virtual fireside chat at the Bank of America Securities 2020 Healthcare Conference on Wednesday, May 13, at 10:20 AM ET (7:20 AM PT).

  • Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7
    PR Newswire

    Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 PM ET.

  • If You Had Bought Arena Pharmaceuticals (NASDAQ:ARNA) Shares Three Years Ago You'd Have Made 283%
    Simply Wall St.

    If You Had Bought Arena Pharmaceuticals (NASDAQ:ARNA) Shares Three Years Ago You'd Have Made 283%

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

  • ESPAÑOL •  Empresas de Cannabis con Acciones el NYSE y NASDAQ: Una Lista Completa
    Benzinga

    ESPAÑOL • Empresas de Cannabis con Acciones el NYSE y NASDAQ: Una Lista Completa

    Articulo via El Planteo.Mientras la industria del cannabis sigue avanzando, mas y mas compañias se mueven para conseguir que sus acciones esten en las listas de las bolsas de valores estadounidenses mas importantes, como NYSE o NASDAQ.El productor de marihuana medicinal canadiense Aphria Inc debuto en la NYSE el 2 de noviembre de 2018. Antes de eso, las acciones de la compañia se vendian como over-the-counter en EEUU y en el Toronto Stock Exchange. Alcanzar las listas de la NYSE es un gran paso para Aphria, abriendose asi a un mayor grupo de inversores.Aphria se une asi a un club relativamente pequeño de compañias de cannabis publicas. Dada la incerteza federal que sigue rodeando al cannabis en Estados Unidos y en la mayoria del mundo, pocas compañias de cannabis eligen el camino de ser listadas publicamente con el objetivo de reunir fondos y aun son menos las que son acciones pure-play (pura y exclusivamente de marihuana).Empresas de Cannabis Publicas y Otras Formas de Recaudar Capital Las compañias de cannabis tipicamente pueden recaudar fondos de firmas de capital de riesgo, o pueden listar sus acciones.Listar una accion permite recaudar fondos de una mayor cantidad de inversores. Al mismo tiempo, una accion negociada publicamente puede resultar volatil, y mas aun en un sector emergente como es el el negocio del cannabis.Aunque figurar en las listas de bolsas de valores importantes como NYSE y NASDAQ requiere acatar reglas de transparencia estricta e imputabilidad, tambien le da a lxs inversorxs una señal de que la compañia va en serio.Contenido Relacionado: Como Invertir en Acciones de Marihuana en Estados Unidos y CanadaNuestro equipo compilo una lista de compañias de cannabis que aparecen en NYSE y NASDAQ, incluyendo una descripcion del desempeño de la empresa en este sector. En la primer parte de la lista, nos concentramos en acciones pure-play, es decir compañias cuyo principal negocio es el cannabis.Akerna Corp (NASDAQ: KERN)Capitalizacion de mercado: USD 91.26 millones Akerna salio a la luz el 17 de junio del 2019, tras la fusion de la compañia enfocada en el cannabis MTech Acquisition Corp, con MJ Freeway, un proveedor de regtech de semillas para la venta y plataforma de Enterprise Resource Planning.Akerna es la primera compañia de regtech que logro ser listada en la NASDAQ y es la primera compañia de cannabis listada en esta bolsa liderada por una mujer. La compañia permite a los negocios de cannabis conectar con puntos de data en la cadena de suministro, proporcionando asi transparentes y confianza.Arena Pharmaceuticals (NASDAQ: ARNA)Capitalizacion de mercado: USD 2.71 mil millonesArena Pharmaceuticals es una compañia de biotecnologia radicada en San Diego, que tiene un segmento de su produccion de medicamentos dedicado a la terapia basada en cannabinoides. Otras partes de su produccion se concentran en drogas no cannabinoideas. El centro de sus operaciones de biotecnologia de cannabis es la investigacion y desarrollo de su candidato a droga de investigacion Olorinab (APD371). Este es un agonista oral completo del receptor cannabinoide 2 que esta siendo investigado para el tratamiento de varios sintomas, principalmente dolor visceral conectado con enfermedades gastrointestinales. Aurora Cannabis Inc. (NYSE: ACB)Capitalizacion de mercado: USD 1.78 mil millones El productor de marihuana canadiense Aurora Cannabis Inc. es considerado una de las mejores acciones con exposicion completa a la industria del cannabis. Aurora es una de las mas grandes compañias de cannabis en el mundo. Opera numerosos establecimientos de produccion licenciados, y posee licencias para la venta y operaciones en una larga lista de paises. La compañia tiene una capacidad de produccion financiada de mas de 500.000 kilogramos. Recientemente adquirio al MedReleaf en una operacion de USD 2.5 mil millones, la mas grande de la industria.Mas informacion sobre como comprar acciones de Aurora Cannabis en la bolsa de valores aqui.Encuentra la lista completa en El Planteo, siguiendo este enalce.Otras empresas en esta lista: * Canopy Growth Corp. (NYSE: CGC) * CannTrust Holdings Inc. (NYSE: CTST) * cbdMD Inc. (NYSE: YCBD) * Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) * Cronos Group Inc. (NASDAQ: CRON) * FSD Pharma Inc. (NASDAQ: HUGE) * Greenlane Holdings, Inc. (NASDAQ: GNLN) * GW Pharmaceuticals PLC (NASDAQ: GWPH) * HEXO Corp. (NYSE: HEXO) * Innovative Industrial Properties Inc. (NYSE: IIPR) * Intec Pharma Ltd. (NASDAQ: NTEC) * NEWAGE (NASDAQ: NBEV) * OrganiGram Holdings Inc. (NASDAQ: OGI) * Pyxus International Inc. (NYSE: PYX) * Sundial Growers Inc. (NASDAQ: SNDL) * Therapix Biosciences Ltd. (NASDAQ: TRPX) * Tilray Inc. (NASDAQ: TLRY) * 22nd Century Group, Inc. (NYSE: XXII) * Village Farms International, Inc. (NASDAQ: VFF) * Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)Y mas!La lista completa, con mas informacion sobre las empresas, en El Planteo.Imagen por Ilona Szentivanyi. Todos los derechos reservados a El Planteo y Benzinga.See more from Benzinga * BioSteel Sends M In Products To Aid Hospitals, First Responders And COVID-19 Patients * ESPAÑOL • Notas Del Día: Charlotte Figi, Epidiolex, Acciones, La Iglesia del Cannabis, Psicodélicos para Salud Mental, y Más * Aurora Cannabis Falls After Announcement Of 12-For-1 Reverse Stock Split(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Arena Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference on April 14
    PR Newswire

    Arena Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference on April 14

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, at 10:40 AM ET (7:40 AM PT).

  • Hedge Funds Have Never Been This Bullish On Arena Pharmaceuticals, Inc. (ARNA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Arena Pharmaceuticals, Inc. (ARNA)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)
    PR Newswire

    Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive topline data from a Phase 1 clinical study evaluating controlled-release delivery profiles (CR) for its investigational agent, etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator.